Clinical trials: CNS
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
- Trial name
- NCT04805983
- Testing
- BMS-984923
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yale University
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Dementia
Intervention Study to Improve Life and Care for People With Dementia and Their Caregivers in Primary Care
Caring for people with dementia and treating them is a major challenge for the health care system in Germany. Among the challenges for population-based health care research are (a) identification and early recognition, (b)…
- Trial name
- DelpHi (NCT01401582)
- Testing
- Implementation of Dementia Care Manager
- Where
- Germany
- Volunteers
- 634 people
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Post-Traumatic Headache
Prazosin for Post-Concussive Headaches
Mild traumatic brain injury (mTBI) caused by blast effects of explosive devices has been called the "signature injury" of soldiers who served in the Iraq and Afghanistan conflicts.
- Trial name
- NCT02965027
- Testing
- Prazosin
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.
- Trial name
- PREFERMS (NCT01623596)
- Testing
- Fingolimod, Disease Modifying therapy
- Where
- 123 sites in United States, Puerto Rico
- Volunteers
- 881 people
- Sponsor
- Novartis Pharmaceuticals
Intracerebral Hemorrhage
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).
- Trial name
- MISTIE-III (NCT01827046)
- Testing
- rt-PA
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 499 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Gait Disorders, Neurologic
Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist.
- Trial name
- NCT04000373
- Testing
- Ekso GT™ exoskeleton
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Cleveland Clinic
Adult Brain Tumors
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma…
- Trial name
- NCT00387894
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Prados
Carotid Artery Disease
A Carotid Stenting Boston Scientific Surveillance Program
CABANA is a multicenter U.S. surveillance registry that will be conducted to compile early clinical outcomes data for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice and to assess the…
- Trial name
- CABANA (NCT00741091)
- Testing
- Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
- Where
- 112 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Boston Scientific Corporation
Parkinson Disease
Study in Parkinson's Disease of Exercise
The purpose of this study is to learn more about the effects of exercise on patients who have been recently diagnosed with Parkinson's disease (PD).
- Trial name
- SPARX (NCT01506479)
- Testing
- Moderate Exercise, Vigorous Exercise, No Intervention
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- University of Colorado, Denver
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer's Disease
Bexarotene Amyloid Treatment for Alzheimer's Disease
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal.
- Trial name
- BEAT-AD (NCT01782742)
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with…
- Trial name
- NCT02580305
- Testing
- SUVN-502, Donepezil, Memantine
- Where
- 71 sites in United States
- Volunteers
- 564 people
- Sponsor
- Suven Life Sciences Limited
Intracranial Aneurysm
Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device
The purpose of this study is to assess the safety and effectiveness of the Pipeline™ device in the treatment of unruptured, wide-neck intracranial aneurysms.
- Trial name
- PREMIER (NCT02186561)
- Testing
- Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device
- Where
- 23 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Parkinson's Disease
Laser Light Cues for Gait Freezing in Parkinson's Disease
The purpose of this study is to gather data to see if the Laser Cane and/or U-Step Walker with laser accessory is more effective in aiding with gait freezing than a regular cane/U-Step Walker in patients who have idiopathic…
- Trial name
- NCT00320242
- Testing
- 1 mo baseline before visual cue
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Beth Israel Deaconess Medical Center
Epilepsy
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
- Trial name
- NCT00368069
- Testing
- Keppra® extended release formulation - XR
- Where
- 34 sites in Brazil, Finland and 5 more
- Volunteers
- 158 people
- Sponsor
- UCB Pharma
Parkinson Disease
Smartphone-based Wearable Telerehabilitation
Parkinson's disease (PD), one of the most common neurological disorders, affects at least 10 million people worldwide. The cardinal motor impairments are tremor, bradykinesia, muscle rigidity, and postural instability.
- Trial name
- NCT04146454
- Testing
- Smartphone-based balance exercises
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Houston
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cerebrovascular Accident
Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors.
- Trial name
- NCT00227994
- Testing
- Galantamine, Donepezil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.